SEARCH

SEARCH BY CITATION

References

  • 1
    Rozendaal L, Walboomers JMM, vanderLinden JC, Voorhorst FJ, Kenemans P, Helmerhorst TJM, van Ballegooijen M, Meuer CJLM. PCR-based high-risk HPV test in cervical cancer screening gives objective risk assessment of women with cytomorphologically normal cervical smears. Int J Cancer 1996; 68: 7669.
  • 2
    Collins S, Mazloomzadeh S, Winter H, Blomfield P, Bailey A, Young LS, Woodman CB. High incidence of cervical human papillomavirus infection in women during the first sexual relationship. Br J Obstet Gynecol 2002; 109: 4426.
  • 3
    Paavonen J, Halttunen M, Hansson BG, Nieminen P, Rostila T, Lehtinen M. Prerequisities for human papillomavirus vaccine trial: results of feasibility studies. J Clin Virol 2000; 19: 2530.
  • 4
    Thomas KK, Hughes JP, Kuypers JM, Kiviat NB, Lee SK, Adam DE, Koutsky LA. Concurrent and sequential acquisition of different genital human papillomavirus types. J Infect Dis 2000; 182: 1097102.
  • 5
    Richardson H, Franco E, Pintos J, Bergeron J, Arella M, Tellier P. Determinants of low- and high-risk cervical human papillomavirus infections in Montreal University students. Sex Transm Dis 2000; 27: 7986.
  • 6
    Rousseau MC, Franco EL, Villa LL, Sobrinho JP, Termini L, Prado JM, Rohan TE. A cumulative case-control study of risk factor profiles for oncogenic and nononcogenic cervical human papillomavirus infections. Cancer Epidemiol Biomarkers Prev 2000; 9: 46976.
  • 7
    Rousseau MC, Abrahamowicz M, Villa LL, Costa MC, Rohan TE, Franco EL. Predictors of cervical coinfection with multiple human papillomavirus types. Cancer Epidemiol Biomarkers Prev 2003; 12: 102937.
  • 8
    Giuliano AR, Pepenfuss M, Abrahamsen M, Inserra P. Differences in factors associated with oncogenic and nononcogenic human papillomavirus infection at the United States-Mexico border. Cancer Epidemiol Biomarkers Prev 2002; 11: 9304.
  • 9
    Samoff E, Koumans EH, Markowitz LE, Sternberg M, Sawyer MK, Swan D, Papp JR, Black CM, Unger ER. Association of Chlamydia trachomatis with persistence of high-risk types of human papillomavirus in a cohort of female adolescents. Am J Epidemiol 2005; 162: 66875.
  • 10
    Luostarinen T, af Geijersstam V, Bjørge T, Eklund C, Hakama M, Hakulinen T, Jellum E, Koskela P, Paavonen J, Pukkala E, Schiller JT, Thoresen S, et al. No excess risk of cervical carcinoma among women seropositive for both HPV16 and HPV6/11. Int J Cancer 1999; 80: 81822.
  • 11
    Luostarinen T, Lehtinen M, Bjørge T, Abeler V, Hakama M, Hallmans G, Jellum E, Koskela P, Lenner P, Lie AK, Paavonen J, Pukkala E, et al. Joint effects of different human papillomaviruses and Chlamydia trachomatis infections on risk of squamous cell carcinoma of the cervix uteri. Eur J Cancer 2004; 40: 105865.
  • 12
    Haavio-Mannila E, Kontula O, Kuusi E. Trends in sexual life. Working papers E 10/2001. The Population Research Institute, Helsinki, 2001.
  • 13
    Laukkanen P, Koskela P, Pukkala E, Dillner J, Läärä E, Knekt P, Lehtinen M. Time trends in incidence and prevalence of human papillomavirus type 6, 11 and 16 infections in Finland. J Gen Virol 2003; 84: 210509.
  • 14
    Anttila A, Pukkala E, Söderman B, Kallio M, Nieminen P, Hakama M. Effect of organised screening on cervical cancer incidence and mortality in Finland, 1963–1995: recent increase in cervical cancer incidence. Int J Cancer 1999; 83: 5965.
  • 15
    Finnish Cancer Organizations. Available at www.cancer.fi
  • 16
    Iwasawa A, Nieminen P, Lehtinen M, Paavonen J. Human papillomavirus DNA in uterine cervix squamous cell carcinoma and adenocarcinoma detected by polymerase chain reaction. Cancer 1996; 77: 22759.
  • 17
    Lehtinen M, Paavonen J. Effectiveness of preventive human papillomavirus vaccination. Int J STD AIDS 2003; 14: 78792.
  • 18
    Garnett GP. Role of herd immunity in determining the effect of vaccines against sexually transmitted disease. J Infect Dis 2005; 191: 97106.
  • 19
    Koskela P, Anttila T, Bjørge T, Brunsvik A, Dillner J, Hakama M, Hakulinen T, Jellum E, Lehtinen M, Lenner P, Luostarinen T, Pukkala E, et al. Chlamydia trachomatis infection as a risk factor for invasive cervical cancer. Int J Cancer 2000; 85: 359.
  • 20
    Dillner J, Kallings I, Brihmer C, Sikström B, Koskela P, Lehtinen M, Schiller JT, Sapp M, Mårdh PA. Seropositivies to human papillomavirus types 16, 18, or 33 capsids and to Chlamydia trachomatis are markers of sexual behaviour. J Infect Dis 1996; 173: 13948.
  • 21
    Kjellberg L, Wang Z, Wiklund F, Edlund K, Ångström T, Lenner P, Sjöberg I, Hallmans G, Wallin K-L, Sapp M, Schiller J, Wadell G. Sexual behaviour and papillomavirus exposure in cervical intraepithelial neoplasia: a population-based case-control study. J Gen Virol 1999; 80: 3918.
  • 22
    Sigstad E, Lie A-K, Luostarinen T, Dillner J, Jellum E, Lehtinen M, Thoresen S, Abeler V. A prospective study of the correlation of prediagnostic human papilomavirus seropositivity and HPV DNA presence in subsequently occurring cervical cancers. Br J Cancer 2002; 87: 17580.
  • 23
    af Geijersstam V, Kibur M, Wang Z, Koskela P, Pukkala E, Schiller J, Lehtinen M, Dillner J. Stability over time of serum antibody levels to human papillomavirus type 16. J Infect Dis 1998; 177: 171014.
  • 24
    Cowan FM, Johnson AM, Ashley R, Corey L, Mindel A. Antibody to herpes simplex virus type 2 as serological marker of sexual lifestyle in populations. BMJ 1994; 309: 13259.
  • 25
    Lehtinen M, Koskela P, Jellum E, Bloigu A, Anttila T, Hallmans G, Luukkaala T, Thoresen S, Youngman L, Dillner J, Hakama M. Herpes simplex virus and risk of cervical cancer: a longitudinal, nested case-control study in the nordic countries. Am J Epidemiol 2002; 156: 68792.
  • 26
    Pukkala E, Gustavsson N, Teppo L. Atlas of cancer incidence in Finland 1953–82. Publication No. 37. Cancer Society of Finland, Helsinki, 1987.
  • 27
    Pukkala E, Söderman B, Okeanov A, Storm H, Rahu M, Hakulinen T, Becker N, Stabenow R, Bjarnadottir K, Stengrevics A, Gurevicius R, Glattre E. Cancer atlas of Northern Europe. Publication No. 62. Cancer Society of Finland, Helsinki, 2001.
  • 28
    Becker N. Cancer mapping: why not use absolute scales. Eur J Cancer A 1994; 30: 699706.
  • 29
    Auvinen E, Niemi M, Malm C, Zilliacus R, Trontti A, Fingerroos R, Lehtinen M, Paavonen B. High prevalence of HPV among female students in Finland. Scand J Infect Dis 2005; 37: 8736.
  • 30
    Pagliusi SR, Quint W, Pawlita M, Dillner J, Wheeler CM, Ferguson M. International standards for HPV DNA and serological evaluation. Vaccine, in press.
  • 31
    Barnabas R, Laukkanen P, Koskela P, Pukkala E, Lehtinen M, Garnett GP. The epidemiology of HPV16 and cervical carcinoma in Finland and the potential impact of vaccination: mathematical modelling analyses. PLoS Med 2006; 3: e138.
  • 32
    Garnett GP, Dubin G, Slaoui M, Darcis T. The potential epidemiological impact of a genital herpes vaccine for women. Sex Transm Infect 2004; 80: 249.
  • 33
    Ho GYF, Burk RD, Klein S, Kadish AS, Chang CJ, Palan P, Basu J, Tachezy R, Lewis R, Romney S. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 1995; 87: 136571.
  • 34
    Ho GYF, Bierman R, Beardsley L. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998; 338: 4238.
  • 35
    Moscicki A-B, Ellenberg JH, Farhat S, Xu J. Persistence of human papillomavirus infection in HIV-infected and -uninfected adolescent girls: risk factors and differences, by phylogenetic type. J Infect Dis 2004; 190: 3745.
  • 36
    Franco EL, Villa LL, Ruiz A, Costa M. Transmission of cervical human papillomavirus infection by sexual activity: differences between low and high oncogenic risk types. J Infect Dis 1995; 172: 75663.
  • 37
    Nowak MA, May RM. Superinfection and the evolution of parasite virulence. Proc R Soc London Ser B 1994; 255: 819.
  • 38
    May RM, Nowak MA. Coinfection and the evolution of parasite virulence. Proc Biol Sic 1995; 261: 20915.